Stimulation of natural killer cells with an anti-CD137 antibody enhances the efficacy trastuzumab, cetuximab, and rituximab in HER2-expressing breast cancer, EGFR plus head and neck cancer, and CD20+lymphoma Kohrt, H., Houot, R., Weiskopf, K., Goldsteini, M., Lund, P., Czerwinski, D., Sunwoo, J., Tedder, T., Chen, L., Levy, R. AMER ASSOC CANCER RESEARCH. 2012

View details for DOI 10.1158/1538-7445.AM2012-LB-138

View details for Web of Science ID 000209701500249